戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 imulating the dopamine release that produces euphoria.
2 d amphetamine produced positive symptoms and euphoria.
3 ntribute to psychosis, thought disorder, and euphoria.
4 sponses, including cognitive alterations and euphoria.
5 iating their effects in both pain relief and euphoria.
6 e to cocaine and/or an enhanced induction of euphoria.
7 g adults' vulnerability to opioid-associated euphoria.
8 reasingly used to avert withdrawal or induce euphoria.
9 ty to loss, and this was not correlated with euphoria.
10 commonly dizziness (59%), paresthesia (34%), euphoria (30%), and hypoesthesia (30%).
11 binoid drugs, with consequences that include euphoria, analgesia, sedation and memory impairment.
12 nd the type II alcoholics reported increased euphoria and a greater likelihood of drinking.
13   PG also showed blunted amphetamine-induced euphoria and alertness compared with HV.
14 ing order, providing self-report measures of euphoria and arousal at regular intervals.
15 ain networks associated with cocaine-induced euphoria and cocaine-induced craving.
16 ed brain circuitry mediating cocaine-induced euphoria and craving using functional MRI (fMRI).
17 ring associations between drug reinforcement/euphoria and discreet or diffuse cues in the drug-taking
18 ive and subjective opioid effects, including euphoria and drug liking, in opioid-experienced adults.
19 ings (N = 246) - and three intention types - euphoria and energy (N = 302), self-insight (N = 219), m
20 socio-emotional benefits than members of the euphoria and energy cluster.
21 ATEMENTCannabis sativa, or marijuana, causes euphoria and exerts a wide range of medicinal benefits.
22                         Thus, MDMA increased euphoria and feelings of sociability, perhaps by reducin
23 ed questionnaires. As expected, MA increased euphoria and feelings of well-being. MA had minimal effe
24 in coupled receptor that mediates analgesia, euphoria and other important central and peripheral neur
25  (SSRT) reported greater amphetamine-induced euphoria and stimulation than those with shorter SSRT.
26 at least one cardinal mania criterion (i.e., euphoria and/or grandiosity) to ensure differentiation f
27 rcement, subjectively linked to drug-induced euphoria, and negative reinforcement, subjectively linke
28 increases receptor affinity, alcohol-induced euphoria, and risk for alcohol use disorders.
29 ve effects on thought disorder, arousal, and euphoria; and (3) amphetamine and ketamine had less-than
30 unner's high as a sudden pleasant feeling of euphoria, anxiolysis, sedation, and analgesia.
31 iting reactions were neurologic (somnolence, euphoria, ataxia) and associated with the infusion.
32 a recreational drug commonly used to enhance euphoria, but it is also used in non-party settings with
33  thousands of years to manage pain and cause euphoria, but their use has been highly limited due to s
34 ) is central to hedonic balance and produces euphoria by engaging reward circuits.
35 cannabinoid or opioid receptor blockage, and euphoria cannot be studied in mouse models.
36                           SA did not produce euphoria, cognitive deficits, or changes in vital signs.
37 d not change MOR binding, although increased euphoria correlated with decreased receptor binding.
38 ll number of study participants, showed that euphoria, disinhibition, and nighttime behaviors were si
39 rus during the inhibition task reported more euphoria during the amphetamine sessions.
40 eart rate and blood pressure and feelings of euphoria (eg, 'High' and 'Like Drug').
41 irritability/lability, agitation/aggression, euphoria/elation, aberrant motor behaviour, hypersexuali
42 ization, tolerance, physical dependence, and euphoria/elation.
43 a single dose of the drug is associated with euphoria, elevated self-confidence, and heightened senso
44                 After a transitory period of euphoria engendered by the improved prognosis of pneumoc
45 ocaine-induced fear compared with those with euphoria had greater increases in left amygdalar CBF.
46 (m-CPP) produced increases in activation and euphoria in depressed patients with SAD, but not in pati
47 sm whereby cocaethylene produces a decreased euphoria in humans compared to cocaine.
48 algesic tolerance or withdrawal in mice, nor euphoria in humans, at clinically-relevant doses.
49 nt monoamine releaser that produces an acute euphoria in most individuals.
50 subjects reported subjective stimulation and euphoria in response to cocaine administration.
51 n-drug (placebo) session was correlated with euphoria induced by MA (on the MA session).
52 e to tactile stimuli, gustatory stimuli, and euphoria-inducing drugs is consistent with a contributio
53 ate positively with fear and negatively with euphoria intensity.
54          Mania is accompanied by symptoms of euphoria, irritability, or excitation, whereas depressio
55     People typically drink alcohol to induce euphoria or reduce anxiety, and they frequently drink in
56  behavioral states, including disinhibition, euphoria, or elaborate stereotypies, whereas dopamine de
57 ed phenotype defined by a preference for all euphoria-producing drugs.
58 ced (1) significant increases in "activation-euphoria" ratings only in depressed patients with SAD in
59                                              Euphoria-related AEs were uncommon (1.2%).
60        The abnormal m-CPP-induced activation-euphoria responses represent a replicated state marker o
61 fects on subjective measures of stimulation, euphoria, reward (liking and wanting), sedation, and neu
62 ess, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusio
63 on between cue-induced neural activation and euphoria was not apparent on the MA session.
64                             Thus, MA-induced euphoria was related to reward cue-elicited neural activ